Competing interests
K.E. is a consultant for AbbVie, Incyte Corporation, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi and Viela Bio. H.L. has served as an advisor, consultant, investigator and/or speaker for AbbVie, Incyte Corporation, L’Oréal, Pfizer and Vita Imaging. V.E. has served as a consultant, investigator and/or speaker for AbbVie, Almirall, Beiersdorf, Boehringer Ingelheim, CeraVe, Galderma, Genesis Pharma, Incyte Corporation, La Roche-Posay, L’Oréal, Merck/MSD, Novartis, Pfizer and Takeda; is the representative for clinical trials of the Research Subcommittee of the Executive Committee of the British Association of Dermatologists (BAD); is a West Midlands BAD Representative (trustee of the BAD); has held a position of interest for the Trial Generation and Prioritisation Panel (UK Dermatology Clinical Trials Network); and is the NIHR West Midlands RRDN Dermatology Specialty Lead. S.R.D. has received fees and/or honoraria as a consultant for Almirall, Avita, Bristol Myers Squibb, Cassiopea SpA, Dermavant Sciences, Dermira, Ferndale Laboratories, Foamix, Galderma Laboratories LP, Incyte Corporation, MC2 Therapeutics, Ortho Dermatologics, Pfizer, Scientis, Sente Labs, SkinCeuticals LLC, UCB and Verrica Pharmaceuticals; has received stock options as a consultant for Gore Range Capital; has received honoraria as a speaker for Almirall and Ortho Dermatologics; has received grants or research funding as an investigator for AbbVie, AOBiome LLC, Atacama Therapeutics, Brickell Biotech, Dermavant Sciences, Incyte Corporation, Novan and SkinMedica; has served as an advisory board member for the Foundation for Research & Education of Dermatology; is a stockholder of Gore Range Capital; and is a shareholder in PDP of Texas. T.P. has received grants and/or honoraria from AbbVie, Aclaris Therapeutics, ACM Pharma, Almirall, Amgen, Astellas, Beiersdorf, Bristol Myers Squibb, Calypso, Celgene, Eli Lilly, First Tracks Biotherapeutics, Galderma, Genzyme, GSK, Incyte Corporation, ISIS Pharma, Janssen, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Priovant Therapeutics, Roivant, Sanofi, Sun Pharmaceuticals, SVR, Takeda UCB, and Vyne Therapeutics; is the cofounder of NIKAIA Pharmaceuticals; is the founder of SUNLUTION; and has patents on WNT agonists and GSK3β antagonists for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. J.R. has served as an advisor, consultant and/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, L’Oréal, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma and UCB and served as an investigator for AbbVie, Alumis, Amgen, Apogee, Aristea, ASLAN, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, Dice Therapeutics, Eli Lilly, Incyte Corporation, Innovaderm, Janssen, Kymera, Kyowa Kirin, LEO Pharma, Merck, Novartis, Oruka, Pfizer, Sanofi Genzyme, Sun Pharma, Takeda and UCB. N.v.G. received grants and/or is a consultant and/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, First Tracks Biotherapeutics, Idorsia, Incyte Corporation, Merck/MSD, Novartis, Pfizer, Takeda and Teva and is chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology. A.W. has served as consultant and/or investigator for AbbVie, Incyte Corporation, Merck/MSD, Novartis, Pfizer, Philips and UCB; has received equipment from Humeca and PerfAction; and has served on advisory boards for AbbVie and Incyte Corporation. C.L. has served as a speaker or consultant or advisor or investigator or received honoraria from AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Devonian, Eli Lilly, Fresenius Kabi, Galderma, GSK, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche-Posay, LEO Pharma, L’Oréal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, TEVA, Tribute, UCB, Valeant, Viatris and Volo Health. M.A. reports consulting fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz and UCB. J.L.L.-E. has served as a consultant, participated in clinical trials and/or received lecture fees from AbbVie, Almirall, Babé, Bioderma, Galderma, Incyte Corporation, Invasix, Isdin, Janssen, LEO Pharma, Lilly, Novartis, Pierre Fabre and UCB. P.G. has served as a consultant for Aclaris Therapeutics, Clarify Medical, DermaForce, Incyte Corporation, Proctor & Gamble and Versicolor Technologies and as a principal investigator for Aclaris Therapeutics, Allergan/SkinMedica, Clinuvel Pharmaceuticals, Incyte Corporation, Johnson & Johnson, L’Oréal, Merz Pharma, Pfizer, Thync Global Inc. and VT Cosmetics. D.R. has served as a consultant, speaker or investigator for AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant Sciences, Dermira, Dualitas, EMD Serono, Galderma, Incyte Corporation, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT Therapeutics, Recludix, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio and Zura Bio. K.B., S.W., S.K. and D.K. are employees and shareholders of Incyte Corporation. A.G.P. has served as an investigator for Avita, Clinuvel and Incyte Corporation; has served as a consultant for AbbVie, Avita, Boehringer Ingelheim, Incyte Corporation, Lilly, Pfizer, Sun Pharma, Thalocan, Villaris, Vimela, Vyne and WCG; and is a shareholder of Tara Medical.
